Creative Medical Technology Holdings secures $4.2M from warrant exercises

Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) announced agreements with warrant holders for the immediate exercise of outstanding warrants to purchase up to 1,116,136 shares of common stock at $3.75 per share. The transaction is expected to generate approximately $4.2 million in gross proceeds before fees.

The warrants were originally issued in March 2025, and the shares issuable upon exercise are registered under an effective Form S-3 registration statement. Roth Capital Partners serves as the company's financial advisor for the transaction.

In exchange for the immediate cash exercise, Creative Medical Technology will issue new unregistered warrants exercisable for up to 2,790,340 shares of common stock at $3.75 per share. The new warrants' exercise price is subject to reduction to the lowest volume-weighted average price of the company's stock during the five trading days following issuance.

The new warrants will be exercisable for five years following shareholder approval. The company also agreed to reduce the exercise price of certain warrants issued in May 2022 to $4.73 per share.

The transaction is expected to close on or about October 29, 2025, subject to customary closing conditions. Creative Medical Technology intends to use net proceeds for working capital and general corporate purposes.

The new warrants were offered through a private placement under Securities Act exemptions and have not been registered with the Securities and Exchange Commission. The company has agreed to file a registration statement covering the resale of shares issuable upon exercise of the new warrants.

Creative Medical Technology Holdings is a clinical-stage biotechnology company focused on regenerative medicine solutions.

You May Also Be Interested In

• SpaceX files for 555.56M share IPO at $135/sh
• Beyond Meat director resigns from board after seven months
• LIXTE Biotechnology raises $16.6 million through registered direct offering